This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n10http://linked.opendata.cz/resource/domain/vavai/projekt/
n7http://linked.opendata.cz/resource/domain/vavai/subjekt/
n6http://linked.opendata.cz/ontology/domain/vavai/
n18http://linked.opendata.cz/resource/domain/vavai/zamer/
n21http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F13%3A10189797%21RIV14-MZ0-00064165/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n8http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n20http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F13%3A10189797%21RIV14-MZ0-00064165
rdf:type
skos:Concept n6:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1371/journal.pone.0053996
dcterms:description
Objectives: To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. Methods: We analyzed 211 CIS patients (age: 28.9 +/- 7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months. Results: The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies. Conclusions: Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy. Objectives: To investigate the associations of environmental MS risk factors with clinical and MRI measures of progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event. Methods: We analyzed 211 CIS patients (age: 28.9 +/- 7.8 years) enrolled in the SET study, a multi-center study of high-risk CIS patients. Pre-treatment samples were analyzed for IgG antibodies against cytomegalovirus (anti-CMV), Epstein Barr virus (EBV) early nuclear antigen-1 (EBNA-1), viral capsid antigen (VCA), early antigen-diffuse (EA-D), 25 hydroxy-vitamin D3 and cotinine levels and HLA DRB1*1501 status. The inclusion criteria required evaluation within 4 months of the initial demyelinating event, 2 or more brain MRI lesions and the presence of two or more oligoclonal bands in cerebrospinal fluid. All patients were treated with interferon-beta. Clinical and MRI assessments were obtained at baseline, 6, 12, and 24 months. Results: The time to first relapse decreased and the number of relapses increased with anti-CMV IgG positivity. Smoking was associated with increased number and volume of contrast-enhancing lesions (CEL) during the 2-year period. The cumulative number of CEL and T2 lesions during the 2-year period was greater for individuals in the highest quartile of anti-EBV VCA IgG antibodies. The percent loss of brain volume was increased for those in the highest quartile of with anti-EBV VCA IgG antibodies. Conclusions: Relapses in CIS patients were associated with CMV positivity whereas anti-EBV VCA positivity was associated with progression on MRI measures, including accumulation of CEL and T2 lesions and development of brain atrophy.
dcterms:title
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study
skos:prefLabel
Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study
skos:notation
RIV/00064165:_____/13:10189797!RIV14-MZ0-00064165
n6:predkladatel
n7:ico%3A00064165
n3:aktivita
n14:Z n14:P
n3:aktivity
P(NT13237), Z(MSM0021620849)
n3:cisloPeriodika
1
n3:dodaniDat
n20:2014
n3:domaciTvurceVysledku
n11:4511042 n11:6253393 n11:8309213 n11:8895465 n11:6857108 n11:8441456
n3:druhVysledku
n16:J
n3:duvernostUdaju
n13:S
n3:entitaPredkladatele
n21:predkladatel
n3:idSjednocenehoVysledku
73028
n3:idVysledku
RIV/00064165:_____/13:10189797
n3:jazykVysledku
n19:eng
n3:klicovaSlova
age; diagnosis; infection; antibodies; cytomegalovirus; smoking; risk-factors; brain atrophy; multiple-sclerosis; epstein-barr-virus
n3:klicoveSlovo
n4:age n4:cytomegalovirus n4:smoking n4:epstein-barr-virus n4:antibodies n4:brain%20atrophy n4:risk-factors n4:infection n4:diagnosis n4:multiple-sclerosis
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[B16363A41293]
n3:nazevZdroje
PLoS ONE
n3:obor
n9:FH
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
21
n3:projekt
n10:NT13237
n3:rokUplatneniVysledku
n20:2013
n3:svazekPeriodika
8
n3:tvurceVysledku
Bergsland, Niels Zhang, Ming Tamano-Blanco, Miriam Yu, Haoying Qu, Jun Horáková, Dana Badgett, Darlene Zivadinov, Robert Hussein, Sara Kalincik, Tomas Krásenský, Jan Duan, Xiaotao Seidl, Zdeněk Weinstock-Guttman, Bianca Týblová, Michaela Willis, Laura Lelková, Petra Dwyer, Michael G. Vaněčková, Manuela Ramanathan, Murali Havrdová, Eva
n3:wos
000313429800079
n3:zamer
n18:MSM0021620849
s:issn
1932-6203
s:numberOfPages
8
n8:doi
10.1371/journal.pone.0053996